Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRobin, Marie
dc.contributor.authorPorcher, Raphael
dc.contributor.authorCiceri, Fabio
dc.contributor.authorvan Lint, Maria Teresa
dc.contributor.authorSantarone, Stella
dc.contributor.authorEhninger, Gerhard
dc.contributor.authorBlaise, Didier
dc.contributor.authorGüllbas, Zafer
dc.contributor.authorGonzáles Muñiz, Soledad
dc.contributor.authorMichallet, Mauricette
dc.contributor.authorVelardi, Andrea
dc.contributor.authorKoster, Linda
dc.contributor.authorMaertens, Johan
dc.contributor.authorSierra, Jorge
dc.contributor.authorSelleslag, Dominik
dc.contributor.authorRadujkovic, Aleksandar
dc.contributor.authorDíez-Martin, José L
dc.contributor.authorKanz, Lothar
dc.contributor.authorArroyo, Concepcion Herrera
dc.contributor.authorNiederwieser, Dietger
dc.contributor.authorHuang, He
dc.contributor.authorMcDonald, Andrew
dc.contributor.authorde Witte, Theo
dc.contributor.authorKoc, Yener
dc.contributor.authorKröger, Nicolaus
dc.identifier.citationBlood Adv.2017 Oct;(1)22:1876-1883
dc.description.abstractThe only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option. The present study reports the European Group for Blood and Marrow Transplantation activity for haploidentical transplantation in MDS patients. A total of 228 patients transplanted from a mismatched HLA-related donor between 2007 and 2014 were studied. The median age at transplant was 56 years. Eighty-four (37%) patients had MDS transformed into acute myeloid leukemia at the time of transplant. Ex vivo T-cell depletion was used in 34 patients. One hundred ninety-four patients received a T-cell replete transplant and 102 patients received posttransplant cyclophosphamide (PT-CY) as graft-versus-host disease (GVHD) prophylaxis. The cumulative incidences of acute and chronic GVHD in PT-CY vs other patients were 25% vs 37% and 37% vs 24%, respectively. The cumulative incidence of nonrelapse mortality was 55% in patients who did not receive PT-CY (no PT-CY) and 41% in patients who did receive PT-CY. Three-year overall survival was 28% in no PT-CY patients and 38% in PT-CY patients. In multivariable analysis, the main risk factors were the intensity of the conditioning regimen and the use of PT-CY. In conclusion, the outcomes of MDS patients who received an haploidentical transplant are close to the results other transplantations from HLA-mismatched donors with approximately one-third of patients alive and free of disease 3 years after transplant, and the use of PT-CY may improve their outcomes.
dc.titleHaploidentical transplant in patients with myelodysplastic syndrome.
dc.identifier.journalBlood advances
dc.pubmedtypeJournal Article
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5728144.pdf1.11 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.